TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS

• US 20100158877A1
• Filed: 12/19/2009
• Published: 06/24/2010
• Est. Priority Date: 12/19/2008
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Ward, Christine K., Gosiewska, Anna, Colter, David C., Kihm, Anthony J.
• Granted Patent: US 10,557,116 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/42 Respiratory system, e.g. lungs, bronchi or lung cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2430/22 for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources

Abstract

Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.

Claims

1. A method of treating a patient having a lung disease, disorder or injury, the method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the lung disease, disorder, or injury, and the damage caused thereby, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.

2. The method of claim 1, wherein the lung disease, disorder or injury is, or is caused by, obstructive diseases or disorders, restrictive diseases or disorders, or direct or indirect injuries.

6. The method of claim 1, wherein the cells are induced in vitro to differentiate into a lung tissue.

7. The method of claim 1, wherein the cells are administered with at least one other cell type.

8. The method of claim 7, wherein the other cell type is a lung tissue cell selected from lung progenitor cell, vascular smooth muscle cell, vascular smooth muscle progenitor cell, pericyte, vascular endothelial cell, vascular endothelium progenitor cell, or other multipotent or pluripotent stem cell.

9. The method of claim 1, wherein the cells are administered with at least one other agent.

10. The method of claim 9, wherein the agent is an antithrombogenic agent, an anti-inflammatory agent, an immunosuppressive agent, an immunomodulatory agent, a pro-angiogenic agent, or an antiapoptotic agent.

11. The method of claim 2, wherein the cells are administered at the sites of the lung disease, disorder or injury.

12. The method of claim 1, wherein the umbilical cord tissue-derived cells are administered by injection, infusion, a device implanted in the patient, or by implantation of a matrix or scaffold containing the cells.

13. The method of claim 1, wherein the cells exert a trophic effect on the lung tissue of the patient.

14. The method of claim 1, wherein the cells exert a trophic effect on the vascular smooth muscle of the patient.

15. The method of claim 14, wherein the trophic effect is proliferation of the vascular smooth muscle cells.

16. The method of claim 1, wherein the cells exert a trophic effect on the vascular endothelium of the patient.

17. The method of claim 16, wherein the trophic effect is proliferation of the vascular endothelial cells.

18. The method of claim 1, wherein the cells induce migration of vascular endothelial cells to the sites of the lung disease, disorder or injury.

19. The method of claim 1, wherein the cells induce migration of vascular endothelium progenitor cells to the sites of the lung disease, disorder or injury.

20. The method of claim 1, wherein the cells induce migration of vascular smooth muscle cells to the sites of the lung disease, disorder or injury.

21. The method of claim 1, wherein the cells induce migration of vascular smooth muscle progenitor cells to the sites of the lung disease, disorder or injury.

22. The method of claim 1, wherein the cells induce migration of pericytes to the sites of the lung disease, disorder or injury.

3. A method of treating a subject having lung disease, said method comprising administering to the patient umbilical cord tissue-derived cells in an amount effective to treat lung disease, wherein said cells are derived from human umbilical cord tissue substantially free of blood and are capable of self-renewal and expansion in culture.

4. The method of claim 3, wherein the umbilical cord tissue-derived cells do not express hTERT or telomerase.

5. The method of claim 3, wherein the umbilical cord tissue-derived cells are negative for CD117.

23. A pharmaceutical composition for treating a patient having a lung disease, disorder or injury, comprising a pharmaceutically acceptable carrier and umbilical cord tissue-derived cells in an amount effective to treat the lung disease, disorder or injury, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.

24. A kit for treating a patient having a lung disease, disorder or injury, the kit comprising a pharmaceutically acceptable carrier, a population of umbilical cord tissue-derived cells and instructions for using the kit in a method of treating the patient, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.

25. A pharmaceutical composition for treating a patient having a lung disease, disorder or injury, which comprises a pharmaceutically acceptable carrier and a preparation made from umbilical cord tissue-derived cells, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a lung tissue.

26. A kit for treating a patient having a lung disease, disorder or injury, the kit comprising the pharmaceutical composition of claim 25.